GOP-Controlled House Could Eye MA Overpayments, ‘Questionable’ Marketing

With a few midterm races unresolved as of mid-November, Democrats are projected to narrowly retain control of the Senate while Republicans will take back the House in the next Congress. That raises numerous questions about the future of health care policy, but D.C. insiders say House Republicans are likely to pursue achievable items rather than reach for the stars. Regardless of who controls each chamber, however, the experts suggested that more accountability and oversight is expected in Medicare Advantage.

“For once, repeal and replace isn’t the defining backbone of Republican health policy in Congress,” said Tarplin, Downs & Young Partner Jennifer Young, referring to multiple GOP efforts to scrap the Affordable Care Act, during a Nov. 4 webinar hosted by Kaiser Family Foundation (KFF). “It took us years, but I think we have learned that repeal and replace was not a winning issue and I think there’s been an acknowledgment that a Democratic president…isn’t likely to sign repeal and replace into law,” said Young, who served as assistant secretary for legislation at HHS and senior counselor to then-Secretary Mike Leavitt during the George W. Bush administration.

© 2022 MMIT
Lauren Flynn Kelly

Lauren Flynn Kelly Managing Editor, Radar on Medicare Advantage

Lauren has been covering health business issues, including drug benefits and specialty pharmacy, for more than a decade. She served as editor of Drug Benefit News (the predecessor to Radar on Drug Benefits) from 2004 to 2005 and again from 2011 to 2016, and now manages Radar on Medicare Advantage. Lauren graduated from Vassar College with a B.A. in English.

Related Posts

medicare-enrollment-form
September 15

RFI Commenters Envision More Plan Flexibility, Improved Transparency in MA

READ MORE
people-outside-the-supreme-court
July 7

On SCOTUS Refusal to Review UHC Case, MAOs Must Tighten Chart Review and Coding Practices

READ MORE
post-default-image
February 4

MA Organizations Can Expect Biden Administration to Revisit RADV Rule

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today